June 18, 2025, Shenzhen - With the increasing aging population, the medical grade silicone market is experiencing explosive growth. The "silicone rubber polylactic acid composite stent" developed by a certain enterprise has completed clinical trials, and its 6-month degradation rate can be controlled at 40% -60%, providing new material solutions for high-end medical devices such as cardiovascular stents and nerve repair catheters.


Innovation Breakthrough: Balancing Biocompatibility and Mechanical Properties
Traditional medical silicone has problems such as uncontrollable degradation cycles and susceptibility to inflammatory reactions. The new composite material introduces polylactic acid side chains into the siloxane main chain through molecular design, which not only maintains the flexibility of silicone rubber but also endows it with controllable degradation characteristics. Animal experiments have shown that the infiltration of macrophages around the implant material is reduced by 67% compared to traditional products, and the speed of vascular endothelialization is doubled.


Market prospect: Accelerated domestic substitution
At present, the global medical grade silicone market is monopolized by a foreign company, and the price of silicone used for cardiac occluders is as high as $800 per gram. After achieving breakthroughs in domestic materials, the cost of the same product can be reduced to below $300. According to Frost&Sullivan's prediction, the size of China's medical silicone market will expand at a compound annual growth rate of 18.7% from 2025 to 2030, reaching 22 billion yuan by 2030.